JR-441

Small molecule

JJCR Pharmaceuticals Co., Ltd.

JR-441 is one of 27 small molecule programs targeting Mucopolysaccharidosis. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MucopolysaccharidosisActive, not recruiting

MucopolysaccharidosisPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

34 competitors in Mucopolysaccharidosis

#DrugCompanyPhaseTrials

Trexall

Alnylam Pharmaceuticals

Approved

1 2

Rituxan

Roche

Approved

1 3

Neoral

Novartis

Approved

—4

Imuran

LLegacy Health System

Immunoglobulin

1 6

BMN 333

BioMarin Pharmaceutical

Phase 3

5 7

ELAPRASE

Takeda

Approved

2 8

ELAPRASE

Takeda

Phase 3

2 9

Humira

CCelltrion

Phase 2

1 10

Genotropin

EMD Serono

Phase 2

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 1/2Active, not recruiting

Mucopolysaccharidosis

NCT06095388

Clinical

Trials by Indication[1]

Mucopolysaccharidosis1 trial

Phase I/II Study of JR-441 in Patients With Mucopolysaccharidosis Type IIIA

Active, not recruiting·JJCR Pharmaceuticals Co., Ltd.·Phase 1/2·NCT06095388·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for JR-441. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JR-441 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JR-441. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — JCR Pharmaceuticals Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: JJCR Pharmaceuticals Co., Ltd.

JR-441

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Mucopolysaccharidosis1 trial

References

Drug Info

Quick Facts

Related News